Q2 Earnings Estimate for KYMR Issued By B. Riley

Key Points

• Analysts at B. Riley predict Kymera Therapeutics will report a Q2 2025 earnings per share (EPS) of ($1.01), with the stock receiving a "Strong-Buy" rating and a price target of $60.00.
• The company has shown significant growth, reporting a 114.6% increase in quarterly revenue year-over-year, with earnings of ($0.82) EPS beating consensus estimates.
• Insider trading activity includes a director selling 6,349 shares and another acquiring 317,167 shares, reflecting confidence in the company's potential as insiders own 16.01% of the stock.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at B. Riley issued their Q2 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued on Wednesday, July 30th. B. Riley analyst M. Mamtani anticipates that the company will earn ($1.01) per share for the quarter. B. Riley has a "Strong-Buy" rating and a $60.00 price target on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($4.03) EPS, FY2027 earnings at ($4.56) EPS and FY2028 earnings at ($3.80) EPS.

Several other research analysts also recently issued reports on KYMR. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. BTIG Research restated a "buy" rating and issued a $59.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 26th. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price on the stock. Finally, Jefferies Financial Group set a $64.00 target price on shares of Kymera Therapeutics and gave the company a "buy" rating in a report on Wednesday, June 25th. Two research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $59.11.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $43.75 on Friday. The business has a fifty day moving average price of $43.58 and a two-hundred day moving average price of $36.55. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $53.27. The stock has a market capitalization of $2.85 billion, a PE ratio of -14.11 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm had revenue of $22.10 million during the quarter, compared to analysts' expectations of $11.38 million. During the same period in the prior year, the company earned ($0.69) earnings per share. The company's quarterly revenue was up 114.6% on a year-over-year basis.

Insiders Place Their Bets

In other news, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bvf Partners L. P/Il acquired 317,167 shares of Kymera Therapeutics stock in a transaction dated Monday, June 30th. The shares were acquired at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the acquisition, the director directly owned 2,798,795 shares of the company's stock, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last quarter. Insiders own 16.01% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KYMR. Farther Finance Advisors LLC grew its holdings in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after buying an additional 540 shares during the last quarter. State of Wyoming acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at about $55,000. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after buying an additional 328 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics during the first quarter valued at about $68,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.